States, Local Governments Grappling With Expensive Drugs

State and local governments across the US are grappling with a growing problem—expensive drugs to treat diabetes and obesity are threatening to drain their healthcare budgets, Bloomberg News reported.

State health plans and Medicaid offices are seeing eye-popping bills for Novo Nordisk A/S’s Ozempic, its sister drug Wegovy, and similar medications known as GLP-1s.

State health plans and Medicaid offices are seeing eye-popping bills for Novo Nordisk A/S’s Ozempic, its sister drug Wegovy, and similar medications known as GLP-1s.

They’re a breakthrough for treating two of the most complex chronic health conditions. But with list prices stretching above $1,000 a month, the costs threaten to empty government coffers.

WEEKLY FEATURE : Jose Mari Chan And The Christmas Anthem